Top Page
Biotron
(Sydney:BIT)
Biotron (BIT) vs. iShares MSCI Australia ETF (EWA)
Biotron Business Overview & Revenue Model
Biotron Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.81M | 1.65M | 1.43M | 1.56M | 1.46M | 803.03K |
| Gross Profit | 1.80M | 1.65M | 1.39M | 1.51M | 1.41M | 752.91K |
| EBITDA | -1.39M | -5.04M | -4.88M | -2.73M | -4.56M | -4.27M |
| Net Income | -1.42M | -3.44M | -3.49M | -2.78M | -3.19M | -3.58M |
Balance Sheet | ||||||
| Total Assets | 8.82M | 493.48K | 4.14M | 1.91M | 4.33M | 7.83M |
| Cash, Cash Equivalents and Short-Term Investments | 8.67M | 393.20K | 3.98M | 1.74M | 4.21M | 7.66M |
| Total Debt | 60.82K | 7.13K | 45.27K | 77.24K | 6.35K | 44.02K |
| Total Liabilities | 411.94K | 737.51K | 962.49K | 813.57K | 463.51K | 853.19K |
| Stockholders Equity | 8.40M | -244.03K | 3.17M | 1.09M | 3.86M | 6.97M |
Cash Flow | ||||||
| Free Cash Flow | 178.92K | -3.57M | -3.29M | -2.44M | -3.41M | -3.08M |
| Operating Cash Flow | 181.99K | -3.57M | -3.29M | -2.44M | -3.41M | -3.08M |
| Investing Cash Flow | -3.07K | 0.00 | 0.00 | 0.00 | -5.72K | 0.00 |
| Financing Cash Flow | -21.72K | -22.62K | 5.53M | -33.17K | -36.96K | 5.00M |
Biotron Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$35.43M | ― | -36.95% | ― | ― | 11.11% | |
50 Neutral | AU$749.49M | ― | -112.97% | ― | ― | -84.82% | |
48 Neutral | AU$2.45B | 3.65 | -64.25% | 2.91% | 35.15% | 13.63% | |
45 Neutral | AU$91.27M | ― | -154.88% | ― | ― | 20.00% | |
44 Neutral | AU$350.49M | ― | -31.16% | ― | ― | 14.47% | |
36 Underperform | $2.65M | ― | -119.28% | ― | ― | 64.10% |
Biotron Corporate Events
Biotron Limited has announced a change in its company secretary position, with Peter J. Nightingale resigning and Marcelo Mora taking over the role. This change, approved by the Board of Biotron Limited, signifies an administrative shift within the company, potentially impacting its operational management and stakeholder relations.
Biotron Limited has initiated an Entitlement Issue to raise funds, securing $1,274,589 to support its antiviral program commercialization, including its lead asset BIT225, and to expand its Hepatitis B virus program. The company continues to collaborate with C14 Consulting Group LLC to refine its commercialization strategy and achieve strategic partnerships, leveraging data from recent clinical trials to drive business development.
Biotron Limited announced a change in the director’s interest notice for Michael J. Hoy, Michelle Miller, and Robert Thomas, as per the ASX Listing Rule 3.19A. The notice, approved by Managing Director Michelle Miller, details the acquisition of ordinary shares by Michael J. Hoy through a rights issue, doubling his holdings to 22,434,705 shares. This change reflects strategic financial maneuvers within the company, potentially impacting its market positioning and shareholder value.
Biotron Limited successfully completed a renounceable rights issue, raising $1,274,589 before costs, and will issue 424,863,077 new fully paid ordinary shares. The funds will support the company’s ongoing commercialisation activities, strategic partnerships for its antiviral programs, and operational costs, demonstrating strong shareholder and management support.
Biotron Limited has announced the dispatch of documents related to its rights issue, which was initially declared on February 28, 2025. The rights issue aims to raise approximately $2.7 million by offering around 902 million new shares at $0.003 each to eligible shareholders in Australia and New Zealand. The offer is open until April 1, 2025, and aims to strengthen the company’s financial position, potentially impacting its market operations and stakeholder interests.
Biotron Limited has updated its timetable for a rights issue initially announced on 28 February 2025. Following feedback from the Australian Securities and Investments Commission (ASIC) and the ASX, a replacement prospectus was lodged on 12 March 2025. The updated schedule outlines key dates, including the opening of the offer on 18 March 2025 and the expected commencement of normal trading of new shares on 9 April 2025. This rights issue provides eligible shareholders the opportunity to acquire additional shares, potentially impacting the company’s capital structure and market position.
Biotron Limited has announced an update to its proposed issue of securities, revising the timetable for its rights issue. The revised schedule includes key dates such as the record date on March 6, 2025, the opening of the offer on March 18, 2025, and the expected commencement of normal trading of new shares on April 9, 2025. This update is significant for stakeholders as it outlines the timeline for the rights issue process, impacting shareholders and potential investors by providing clarity on the investment opportunity and the company’s capital raising efforts.
Biotron Limited has issued a replacement prospectus for a renounceable pro rata offer to eligible shareholders, aiming to raise approximately $2.7 million through the issuance of new shares. The offer is partially underwritten by Mahe Capital Pty Limited for $750,000. This move is intended to strengthen the company’s financial position and provide additional capital for its operations, although the offer is not available to US persons or for sale in the United States.
Biotron Limited has responded to an ASX query regarding its financial disclosures, confirming compliance with accounting standards and the accuracy of its financial position. The company highlighted its dependency on raising additional funds or forming strategic partnerships to maintain operations. Due to delays in securing a partner, Biotron emphasized the need for at least six months of operational cash, leading to a share purchase plan (SPP) to raise necessary capital. The company considered various funding options, ultimately opting for an SPP, and later accepted a partially underwritten rights issue to avoid insolvency.
Biotron Limited has announced an updated timetable for its proposed issue of securities, which includes a revised schedule for the rights issue and the issuance of new shares. The updated dates outline key steps such as the opening of the offer, the end of rights trading, and the commencement of normal trading for the new shares. This announcement is significant as it provides clarity on the company’s capital raising efforts, which could impact its financial position and operational capabilities moving forward.
Biotron Limited has announced a delay in the opening of its rights issue due to queries raised by the Australian Securities and Investments Commission (ASIC). The company now aims to open the rights issue on 17 March 2025, with the revised timetable to be confirmed soon. This delay may impact the company’s fundraising efforts and could influence its operational plans and market positioning.
Biotron Limited has announced a revised timetable for its proposed issue of securities, which is a renounceable pro rata issue. This update reflects changes to the previous announcement made on February 28, 2025, and aims to align with the ASX requirements for quoting securities. The adjustment in the schedule may impact the company’s capital-raising efforts and its strategic positioning in the biotechnology market.
Biotron Limited has announced the commencement of rights trading on the ASX under the ticker code BITR, following a rights issue announced on 28 February 2025. The rights issue offers shareholders in Australia and New Zealand the opportunity to purchase one new share for every share held at $0.003 per share, with the closing date extended to 25 March 2025. This move is expected to provide Biotron with additional capital to further its drug development programs, potentially enhancing its market position in the pharmaceutical industry.
Biotron Limited responded to an ASX query regarding a recent announcement that was mistakenly marked as non-market sensitive due to human error. The announcement included potential financial distress scenarios, which led to a drop in share price. The company has since withdrawn its share purchase plan in favor of a rights issue, ensuring compliance with its disclosure policies and maintaining financial oversight to support ongoing and future research activities.
Biotron Limited has announced a renounceable pro rata offer to its eligible shareholders, aiming to raise approximately $2.7 million through the issuance of new shares. The offer, partially underwritten by Mahe Capital Pty Limited, is intended to strengthen the company’s financial position and support its ongoing operations in the biotechnology sector.
Biotron Limited has reported a significant increase in profit for the half year ended 31 December 2024, with profits rising by 152.62% to $696,629. Despite the positive financial performance, the company did not declare any dividends for the period, and there is a noted material uncertainty that stakeholders should consider.
Biotron Limited has announced the relocation of its principal administrative office to Level 2, 66 Hunter Street, Sydney, NSW 2000, effective 28 February 2025. This move is part of the company’s ongoing efforts to streamline operations and may impact its communication channels, as previous contact numbers have been discontinued. The relocation reflects Biotron’s strategic positioning to enhance its operational efficiency and maintain its competitive edge in the biotechnology sector.
Biotron Limited announced the cancellation of its previous Share Purchase Plan, which was initially proposed as part of a securities issue. This decision may impact the company’s funding strategy and could have implications for its financial planning and stakeholder relations, as the company adjusts its approach to capital raising.
Biotron Limited has announced a renounceable rights issue aiming to raise up to $2.7 million, priced at a significant discount to its recent share value. The funds will be used to support ongoing operations, including strategic partnership efforts with C14 Consulting Group for its antiviral programs, conducting animal studies for its Hepatitis B virus compound, and maintaining and expanding its patent portfolio. The rights issue is partially underwritten by Mahe Capital, and directors plan to participate fully, highlighting confidence in the company’s strategic direction.
Biotron Limited announced the successful completion of its BIT225 HIV-1 Phase 2 clinical trials, which met primary objectives by demonstrating safety and efficacy. The company is advancing its Hepatitis B and Dengue Virus programs, highlighting its potential across multiple infectious diseases. Biotron is also collaborating with C14 Consulting Group to secure strategic partnerships and commercialize its clinical and pre-clinical assets. Additionally, a Share Purchase Plan is being offered to eligible shareholders, providing an opportunity to participate in Biotron’s growth.
Biotron Limited has announced a proposed issue of 270,714,829 ordinary fully paid securities as part of a securities purchase plan. This initiative, set to close on March 12, 2025, and issue on March 19, 2025, aims to enhance the company’s financial resources, potentially strengthening its market position and offering stakeholders an opportunity to invest in Biotron’s future growth and development in the biotechnology industry.
Biotron Limited has announced a Share Purchase Plan (SPP) for eligible shareholders in Australia and New Zealand, allowing them to acquire up to $30,000 worth of new shares at $0.01 per share. The funds raised will support ongoing operations and strategic partnerships, particularly for its antiviral programs and intellectual property expansion. The company is collaborating with C14 Consulting Group LLC to secure partnerships, focusing on antiviral treatments like BIT225 and early-stage programs such as the Hepatitis B virus project. The success of this initiative is vital for Biotron’s future operations and market positioning.
Biotron Limited has announced a Share Purchase Plan (SPP) allowing eligible shareholders in Australia and New Zealand to purchase new shares at $0.01 each, raising funds to support ongoing operations and strategic partnerships. The funds will also bolster the company’s intellectual property and progress its early-stage Hepatitis B programs, with a minimum target to raise $500,000, below which the company may contemplate administration or closure.